Pharvaris Reports the US FDA’s NDA Acceptance of Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Shots: The US FDA has accepted NDA for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of Hereditary Angioedema (HAE) attacks (PDUFA: Apr 23, 2027) NDA was backed by data from >1,300 HAE attacks. In P-III (RAPIDe-3) trial, deucrictibant IR met the 1EP & all eleven 2EPs, with median times to symptom relief,…

ByRidhi RastogiJuly 6, 2026

NEWS

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Shots: Natera has reported the publication of data on Signatera, a personalized MRD test for resected colorectal liver metastases (CRLM), in JAMA Oncology, with findings also presented at the ESMO GI 2026 The analysis incl. 298 pts from the GALAXY trial, an observational arm of CIRCULATE-Japan, assessing outcomes by MRD status & adj. CT (ACT) use…

ByRidhi RastogiJuly 6, 2026

NEWS

Astex Pharmaceuticals Partners with Genentech for Breast Cancer Therapy Program in a Deal Worth Over $490M

Shots: Astex has entered into an exclusive, worldwide research collaboration & license agreement with Genentech to identify small molecules with selective inhibitory activity for the treatment for breast cancer Astex will license compounds from its breast cancer discovery program to Genentech and jointly optimize lead compounds through preclinical candidate selection, after which Genentech will lead…

ByRidhi RastogiJuly 6, 2026

NEWS

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…

ByRidhi RastogiJuly 6, 2026

NEWS

Novartis to Acquire Myricx Bio for ~$1.5B

Shots: Novartis has entered into an agreement to acquire Myricx Bio, strengthening Novartis’ oncology pipeline & advancing next-generation targeted drug conjugates with novel payload mechanisms Myricx is developing ADCs, using NMT inhibitor (NMTi) payloads designed to disrupt key cancer cell processes, with preclinical data showing broad activity across solid tumors, incl. TOPO-1-resistant models As per…

ByRidhi RastogiJuly 6, 2026

NEWS

Ascletis Reports the US FDA’s IND Submission for ASC36 and ASC36_35 FDC to Treat Obesity

Shots: The US FDA has received IND applications for ASC36, a QM to Q3M peptide amylin receptor agonist, & ASC36_35 FDC, a QM injection co-formulation of ASC36 + ASC35, for the treatment of obesity In NHP studies, ASC36 SALD showed ~6-fold longer half-life than eloralintide, supporting QM to Q3M SC dosing, while ASC36_35 FDC SALD…

ByRidhi RastogiJuly 6, 2026

NEWS

PolarityBio Reports the US FDA BLA Submission of SkinTE for Wagner Grade 1 Diabetic Foot Ulcers

Shots: The US FDA has received the BLA of SkinTE for the treatment of Wagner Grade 1 diabetic foot ulcers (DFUs) BLA submission follows the P-III (COVER DFUS II) trial assessing SkinTE + SoC vs SoC alone in 120 pts with Wagner 1 DFU, which met its 1EP of complete wound closure SkinTE is a first-in-class autologous…

ByRidhi RastogiJuly 3, 2026

NEWS

Visby Medical Secures FDA Clearance for At-Home Flu & COVID-19 PCR Test

Shots: The US FDA has granted clearance to Flu and COVID-19 Test, an at-home PCR test capable of detecting multiple respiratory viruses, expanding its portfolio of over-the-counter molecular diagnostics The test delivers PCR-quality results in 30min. & detects COVID-19 and influenza A/B at home, enabling earlier diagnosis & timely treatment decisions, incl. access to antiviral…

ByRidhi RastogiJuly 3, 2026

NEWS

United Therapeutics Acquires Thymmune Therapeutics for ~$300M

Shots: United Therapeutics has acquired Thymmune Therapeutics, incl. its lead asset THY-100, developed for the treatment of congenital athymia Under the deal, United Therapeutics has acquired Thymmune for $140M upfront, with up to $160M in additional earn-out payments tied to clinical & regulatory milestones through 2031 THY-100 is a preclinical regenerative therapy for congenital athymia…

ByRidhi RastogiJuly 3, 2026

NEWS

CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal

Shots: CSPC & AstraZeneca have entered into a strategic collaboration, option & license agreement to leverage CSPC’s siRNA discovery & extrahepatic targeted delivery platforms to develop novel small nucleic acid therapeutics CSPC & AstraZeneca will jointly discover & develop preclinical candidates for two renal disease targets, with AstraZeneca holding options for global/ex-China rights to each…

ByRidhi RastogiJuly 3, 2026

Ridhi Rastogi

Pharvaris Reports the US FDA’s NDA Acceptance of Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Astex Pharmaceuticals Partners with Genentech for Breast Cancer Therapy Program in a Deal Worth Over $490M

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Novartis to Acquire Myricx Bio for ~$1.5B

Ascletis Reports the US FDA’s IND Submission for ASC36 and ASC36_35 FDC to Treat Obesity

PolarityBio Reports the US FDA BLA Submission of SkinTE for Wagner Grade 1 Diabetic Foot Ulcers

Visby Medical Secures FDA Clearance for At-Home Flu & COVID-19 PCR Test

United Therapeutics Acquires Thymmune Therapeutics for ~$300M

CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal

Contact US

FOLLOW US